Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.

<h4>Background</h4>Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymph...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Magdalena Winiarska, Jacek Bil, Ewa Wilczek, Grzegorz M Wilczynski, Malgorzata Lekka, Patrick J Engelberts, Wendy J M Mackus, Elzbieta Gorska, Lukasz Bojarski, Tomasz Stoklosa, Dominika Nowis, Zuzanna Kurzaj, Marcin Makowski, Eliza Glodkowska, Tadeusz Issat, Piotr Mrowka, Witold Lasek, Anna Dabrowska-Iwanicka, Grzegorz W Basak, Maria Wasik, Krzysztof Warzocha, Maciej Sinski, Zbigniew Gaciong, Marek Jakobisiak, Paul W H I Parren, Jakub Golab
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2008
Materias:
R
Acceso en línea:https://doaj.org/article/8a6f737eb02e4bb2b26604dc216cc95b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!